Literature DB >> 7056949

A comparison of immunotherapy schedules for injection treatment of ragweed pollen hay fever.

T E Van Metre, N F Adkinson, F J Amodio, A Kagey-Sobotka, L M Lichtenstein, M R Mardiney, P S Norman, G L Rosenberg.   

Abstract

In 44 patients highly sensitive to ragweed, we compared weekly injections of single doses of ragweed extract (RW-Wk, 15 patients) with clustered doses of ragweed extract at 3-wk intervals (RW-Cl, 18 patients) for effects on ragweed hay fever symptom-medication scores and immunologic variates. Patients were matched and randomly assigned to treatment groups. Ragweed doses were advanced to the highest tolerated dose. Doses and number of visits were lower in the RW-Cl group than in the RW-Wk group. Despite lower doses, systemic reactions were not reduced and antiragweed IgE levels increased significantly more in the RW-Cl group than those in the RW-Wk group. Both the RW-Cl and RW-Wk groups had significant increases in antiragweed IgG levels, decreases in seasonal rise in antiragweed IgE levels, and lower symptom-medication scores (p less than 0.01) in comparison with the placebo group. We conclude that the RW-Cl regimen offered no important advantage over RW-Wk. Seventeen patients had previously received Rinkel-method immunotherapy with 0.5 ml of end-point dilution of ragweed extract for 1 to 2 yr without significant clinical improvement or immunologic changes. After adequate treatment with either RW-Wk or RW-Cl, these patients had significantly lower symptom-medication scores than those of the placebo groups and immunologic changes similar to those of the entire active-treatment group. Therefore, treatment failures on Rinkel immunotherapy respond well to adequate dose immunotherapy by either schedule.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7056949     DOI: 10.1016/0091-6749(82)90098-7

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  6 in total

Review 1.  Allergen injection immunotherapy for seasonal allergic rhinitis.

Authors:  M A Calderon; B Alves; M Jacobson; B Hurwitz; A Sheikh; S Durham
Journal:  Cochrane Database Syst Rev       Date:  2007-01-24

Review 2.  Sublingual immunotherapy and allergic rhinitis.

Authors:  Linda Cox
Journal:  Curr Allergy Asthma Rep       Date:  2008-04       Impact factor: 4.806

Review 3.  Guidelines for the use of allergen immunotherapy. Canadian Society of Allergy and Clinical Immunology.

Authors: 
Journal:  CMAJ       Date:  1995-05-01       Impact factor: 8.262

4.  A comparison of seasonal trends in asthma exacerbations among children from geographic regions with different climates.

Authors:  Julia A Wisniewski; Anne P McLaughlin; Philip J Stenger; James Patrie; Mark A Brown; Jane M El-Dahr; Thomas A E Platts-Mills; Nora J Byrd; Peter W Heymann
Journal:  Allergy Asthma Proc       Date:  2016-11       Impact factor: 2.587

5.  Anaphylaxis after vaccination for cats in Japan.

Authors:  Megumi Yoshida; Keijiro Mizukami; Masaharu Hisasue; Ichiro Imanishi; Keigo Kurata; Masaki Ochiai; Masato Itoh; Tadahiro Nasukawa; Jumpei Uchiyama; Hajime Tsujimoto; Masahiro Sakaguchi
Journal:  J Vet Med Sci       Date:  2021-11-16       Impact factor: 1.267

6.  Allergen immunotherapy decreases interleukin 4 production in CD4+ T cells from allergic individuals.

Authors:  H Secrist; C J Chelen; Y Wen; J D Marshall; D T Umetsu
Journal:  J Exp Med       Date:  1993-12-01       Impact factor: 14.307

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.